Mirum Pharmaceuticals (NASDAQ:MIRM) Reaches New 1-Year Low at $24.17

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) reached a new 52-week low during mid-day trading on Monday . The stock traded as low as $24.17 and last traded at $24.44, with a volume of 13150 shares changing hands. The stock had previously closed at $24.58.

Analysts Set New Price Targets

Several research firms have issued reports on MIRM. JMP Securities upped their price target on Mirum Pharmaceuticals from $69.00 to $72.00 and gave the company an “outperform” rating in a report on Thursday, March 14th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $35.00 price target on shares of Mirum Pharmaceuticals in a report on Thursday, February 29th. Raymond James dropped their price target on Mirum Pharmaceuticals from $78.00 to $64.00 and set a “strong-buy” rating on the stock in a report on Tuesday, December 19th. SVB Leerink dropped their price target on Mirum Pharmaceuticals from $44.00 to $43.00 and set an “outperform” rating on the stock in a report on Monday, March 18th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $58.00 price target on shares of Mirum Pharmaceuticals in a report on Tuesday, April 2nd. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Mirum Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $52.11.

Mirum Pharmaceuticals Price Performance

The stock has a market capitalization of $1.13 billion, a P/E ratio of -6.05 and a beta of 1.14. The stock’s fifty day moving average is $27.10 and its 200-day moving average is $28.59. The company has a debt-to-equity ratio of 1.23, a current ratio of 4.45 and a quick ratio of 4.19.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings results on Wednesday, February 28th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.32). Mirum Pharmaceuticals had a negative net margin of 86.33% and a negative return on equity of 66.24%. The firm had revenue of $69.55 million for the quarter, compared to the consensus estimate of $66.73 million. On average, equities analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.12 earnings per share for the current year.

Insider Buying and Selling at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, COO Peter Radovich sold 4,303 shares of the company’s stock in a transaction dated Monday, March 25th. The shares were sold at an average price of $25.80, for a total transaction of $111,017.40. Following the completion of the sale, the chief operating officer now directly owns 29,013 shares in the company, valued at $748,535.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, CFO Eric Bjerkholt purchased 2,000 shares of the firm’s stock in a transaction on Wednesday, March 27th. The stock was bought at an average cost of $24.80 per share, for a total transaction of $49,600.00. Following the completion of the acquisition, the chief financial officer now directly owns 14,000 shares of the company’s stock, valued at $347,200. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, COO Peter Radovich sold 4,303 shares of the stock in a transaction dated Monday, March 25th. The shares were sold at an average price of $25.80, for a total transaction of $111,017.40. Following the completion of the sale, the chief operating officer now owns 29,013 shares of the company’s stock, valued at approximately $748,535.40. The disclosure for this sale can be found here. Corporate insiders own 24.06% of the company’s stock.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Several hedge funds have recently made changes to their positions in the stock. Los Angeles Capital Management LLC lifted its stake in shares of Mirum Pharmaceuticals by 10.8% in the first quarter. Los Angeles Capital Management LLC now owns 41,836 shares of the company’s stock valued at $1,051,000 after buying an additional 4,069 shares during the period. Healthcare of Ontario Pension Plan Trust Fund lifted its stake in shares of Mirum Pharmaceuticals by 111.9% in the fourth quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 211,949 shares of the company’s stock valued at $6,257,000 after buying an additional 111,949 shares during the period. Vanguard Group Inc. lifted its stake in shares of Mirum Pharmaceuticals by 46.2% in the fourth quarter. Vanguard Group Inc. now owns 2,476,244 shares of the company’s stock valued at $73,099,000 after buying an additional 782,901 shares during the period. Goldman Sachs Group Inc. lifted its stake in shares of Mirum Pharmaceuticals by 89.5% in the fourth quarter. Goldman Sachs Group Inc. now owns 456,318 shares of the company’s stock valued at $13,471,000 after buying an additional 215,542 shares during the period. Finally, Price T Rowe Associates Inc. MD lifted its stake in shares of Mirum Pharmaceuticals by 3,544.3% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,164,682 shares of the company’s stock valued at $34,383,000 after buying an additional 1,132,723 shares during the period.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.